



Press release

Stockholm, 6 May 2015

Bactiguard enters distribution agreement for Israel

Bactiguard has entered an exclusive distribution agreement for Israel with Dover Medical & Scientific Equipment Ltd. The agreement covers sales of all products in the Bactiguard Infection Protection portfolio.

“Changing our market strategy for Israel from direct sales to sales via a distributor is a more cost efficient way of expanding our presence and sales in this market. The number of patients that die from infections caused by resistant bacteria in Israeli hospitals is estimated to more than 4 000 per year, so there is a great need for preventive solutions”, says Niels Christiansen, CEO.

Israel has a population of 8 million people and almost 8 percent of GDP is spent on healthcare. Offering preventive solutions, such as Bactiguard® -coated catheters for the urinary- and respiratory tracts and the bloodstream is vital to combat healthcare associated infections.

The distributor in Israel, Dover Medical & Scientific Equipment, Ltd., is a family owned company founded in 1974. It is one of the leading companies in the Israeli market for medical devices with customers such as: Ministry of Health Hospitals, University Hospitals, Private Hospitals, Clinics and Research Institutes. Dover focuses on medical and diagnostic solutions.

For further information, please contact:

Cecilia Edström, Acting Director of Sales, Marketing & Communications,
mobile: +46 722 262 328

About Bactiguard

Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the Europe, Middle East, Asia, Latin America and Southern Africa. The company has market presence in some 50 countries and has about 60 employees. Its headquarters are located in Stockholm and production facilities in Sweden and Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com.